Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03776071 · ClinicalTrials.gov registry record · Phase 3
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
A Phase 3 study of Glioblastoma, sponsored by Denovo Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT03776071: Completed Phase 3 study of Glioblastoma, sponsored by Denovo Biopharma.
NCT03776071 is a Phase 3 study of Glioblastoma that has completed, run by Denovo Biopharma. The registered enrollment target is 260 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (141% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03776071, a Phase 3 study of Glioblastoma, has completed, sponsored by Denovo Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Enzastaurin Hydrochloride
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine Health Chao Family Comprehensive Cancer Center - Orange
- The University of Southern California - Pasadena
- University of California San Francisco Helen Diller Family Comprehensive CA Ctr - San Francisco
Florida
- Lynn Cancer Institute - Boca Raton
- Mayo Clinic - Jacksonville - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
- Miami Cancer Institute - Miami
- Moffitt Cancer Center - Tampa
Arizona
- Barrow Neurological Institute - Phoenix
- Mayo Clinic - Arizona - Scottsdale
Colorado
- University of Colorado Hospital Anschutz Cancer Pavilion - Aurora
- Blue Sky Neurology - Englewood
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Smilow Cancer Hospital - New Haven - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 3 |
What the finished NCT03776071 record still lists
NCT03776071 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (141% higher).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03776071 names 20 study sites across 9 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03776071 about?
NCT03776071 is a clinical study titled "A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1". This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
What is the current status of trial NCT03776071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2020-12-16. Estimated completion is 2024-02-29.
What conditions does trial NCT03776071 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03776071?
The interventions under investigation include: Placebo (OTHER), Temozolomide (DRUG), Radiotherapy (RADIATION), Enzastaurin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03776071?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03776071 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03776071's enrollment target sits among peer trials
260 23rd of 199 higher than 177 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI